Drugmaker seeks judicial review in CMA excessive-pricing case

The UK antitrust enforcer’s “manifestly” and “irrationally” wrong decision to refuse an extension for a defendant to respond to a supplementary statement of objections should be reviewed by a court, a pharmaceutical company has argued.

Get unlimited access to all Global Competition Review content